 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Silence Therapeutics plc, Nasdaq: SLN (Silence or the Company), an experienced and innovative biotechnology company committed to transforming peoples lives by silencing diseases through precision...

Silence Therapeutics to Participate in Fireside Chat at Chardans 7th Annual Genetic Medicines Conference

In trading on Tuesday, shares of Silence Therapeutics plc (SLN) crossed above their 200 day moving average of 9.19, changing hands as high as 9.42 per share. Silence Therapeutics plc...

Silence Therapeutics (SLN) Shares Cross Above 200 DMA

Silence Therapeutics to Participate in September Investor Conferences

Silence Therapeutics plc (NASDAQ:SLN  Get Free Report) was the target of a significant growth in short interest in the month of August. As of August 15th, there was short interest totalling 125,100 shares, a growth of 24.0% from the July 31st total of 100,900 shares. Based on an average daily...

Short Interest in Silence Therapeutics plc (NASDAQ:SLN) Expands By 24.0%

HC Wainwright reaffirmed their buy rating on shares of Silence Therapeutics (NASDAQ:SLN Free Report) in a report issued on Thursday, Benzinga reports. HC Wainwright currently has a $80.00 price objective on the stock. SLN has been the topic of several other reports. Chardan Capital reissued a buy ...

Silence Therapeutics (NASDAQ:SLN) Receives Buy Rating from HC Wainwright

Where Silence Therapeutics Stands With Analysts

Silence Therapeutics Reports Second Quarter 2023 Results

Silence Therapeutics plc (NASDAQ:SLN  Free Report)  Analysts at William Blair issued their Q1 2024 EPS estimates for Silence Therapeutics in a report released on Thursday, August 3rd. William Blair analyst M. Minter forecasts that the company will post earnings of ($0.46) per share for...

Silence Therapeutics plc Forecasted to Post Q1 2024 Earnings of ($0.46) Per Share (NASDAQ:SLN)

Morgan Stanley reissued their overweight rating on shares of Silence Therapeutics (NASDAQ:SLN  Free Report) in a research report report published on Monday morning, Benzinga reports. Morgan Stanley currently has a $20.00 price target on the stock. Silence Therapeutics Stock Up 5.7 % Shares of...

Silence Therapeutics (NASDAQ:SLN) Earns "Overweight" Rating from Morgan Stanley

Silence Therapeutics: No Reason For It To Fall So Much

Silence Therapeutics Plc engages in the discovery, delivery, and development of ribonucleic acid (RNA) therapeutics. It also develops medicines by harnessing the body's natural mechanism of RNA interference within its cells. The company was founded on November 18, 1994 and is headquartered in London, the United Kingdom.

Watchers	157
52-Wk Low	$4.55
52-Wk High	$17.99

Market Cap	$350.74M
Volume (M)	2,593.00
52-Wk High	$17.99
52-Wk Low	$4.55

SLN Silence Therapeutics Plc - ADR

About

Feed

News

Earnings

Fundamentals